Maintenance of DNA integrity is crucial for all cell types, but neurons are particularly sensitive to mutations in DNA repair genes, which lead to both abnormal development and neurodegeneration 1 . We describe a previously unknown autosomal recessive disease characterized by microcephaly, early-onset, intractable seizures and developmental delay (denoted MCSZ). Using genome-wide linkage analysis in consanguineous families, we mapped the disease locus to chromosome 19q13.33 and identified multiple mutations in PNKP (polynucleotide kinase 3′-phosphatase) that result in severe neurological disease; in contrast, a splicing mutation is associated with more moderate symptoms. Unexpectedly, although the cells of individuals carrying this mutation are sensitive to radiation and other DNA-damaging agents, no such individual has yet developed cancer or immunodeficiency. Unlike other DNA repair defects that affect humans, PNKP mutations universally cause severe seizures. The neurological abnormalities in individuals with MCSZ may reflect a role for PNKP in several DNA repair pathways.
Maintenance of DNA integrity is crucial for all cell types, but neurons are particularly sensitive to mutations in DNA repair genes, which lead to both abnormal development and neurodegeneration 1 . We describe a previously unknown autosomal recessive disease characterized by microcephaly, early-onset, intractable seizures and developmental delay (denoted MCSZ). Using genome-wide linkage analysis in consanguineous families, we mapped the disease locus to chromosome 19q13.33 and identified multiple mutations in PNKP (polynucleotide kinase 3′-phosphatase) that result in severe neurological disease; in contrast, a splicing mutation is associated with more moderate symptoms. Unexpectedly, although the cells of individuals carrying this mutation are sensitive to radiation and other DNA-damaging agents, no such individual has yet developed cancer or immunodeficiency. Unlike other DNA repair defects that affect humans, PNKP mutations universally cause severe seizures. The neurological abnormalities in individuals with MCSZ may reflect a role for PNKP in several DNA repair pathways.
We identified the autosomal recessive disorder MCSZ with the following features: microcephaly, infantile-onset seizures, developmental delay and variable behavioral problems, especially hyperactivity. MCSZ was observed in multiple pedigrees of Middle Eastern and European origin (Fig. 1) . The first three pedigrees were Arabic Palestinians living in Jordan and the United States. Three other families with similar manifestations were Arabic (Kingdom of Saudi Arabia), Turkish and of mixed European ancestry (United States). We later found less severely affected individuals with MCSZ from family 7, which is also mixed European heritage and from the United States. Brain magnetic resonance imaging scans (MRIs) consistently show microcephaly with preserved brain structures, without apparent neuronal migration or other structural abnormalities, and with no evidence of degeneration (Fig. 2) . The affected individuals did not develop ataxia or other neurological symptoms. Routine clinical genetic and metabolic screening showed no abnormalities. Despite careful inquiry, individuals with MCSZ were not found to have a higher frequency of common or uncommon infections, offering no clinical evidence of immunodeficiency. Cells from one affected individual showed sensitivity to irradiation in a standard colony-survival assay 2, 3 . However, no affected person has developed cancer by age 21, and heterozygous carriers have not developed early-onset cancer or any sign of immunodeficiency (Supplementary Note, Clinical Information, Supplementary Table 4 and Summary).
Genome-wide linkage screens suggested a single common homozygous region on chromosome 19q in all six individuals with MCSZ in the consanguineous families 1-3. This same locus showed homozygosity in the two affected individuals from family 4 and in the single one from family 5 whose parents were not known to be related. We observed no other regions of linkage, including at known primary microcephaly loci. Notably, all six affected individuals in the three Palestinian families (families 1-3) were homozygous for the same 3-cM (1.5-Mb) haplotype (between markers D19S879 and D19S907) at chromosome 19q13.33, suggesting a common ancestor (Supplementary Fig. 1 ). Further investigation revealed a common town of origin for these families. Linkage analysis of families 1-4 and family 6 generated a combined maximum two-point lod score of 5.60 at D19S867 with u = 0 (Supplementary Table 1 ) and a maximum multipoint lod score of 7.12 ( Supplementary Fig. 2) .
We sequenced 41 genes within the minimal region ( Supplementary  Fig. 2 and Supplementary Table 2), and only the PNKP gene contained mutations. We found homozygous mutations in families [1] [2] [3] [4] [5] Mutations in PNKP cause microcephaly, seizures and defects in DNA repair l e t t e r s and compound heterozygous mutations in families 6 and 7 (see Fig. 3 and Supplementary Fig. 3 for detailed analyses of all mutations). The three Palestinian families (families 1-3) shared a homozygous base pair substitution in exon 11 (G975A), resulting in the nonconservative amino acid change E326K. The families from the Saudi Arabia (family 4) and Turkey (family 5) had the same homozygous 17-bp duplication (17-bp dup) in exon 14 (1250_1266dup), resulting in a frameshift, T424GfsX48. Family 6 (European) had two heterozygous mutations: the same 17-bp duplication in exon 14 as the Saudi and Turkish families and a point mutation in exon 5 (C526T) that results in L176F. The moderately affected members of family 7 (European) showed compound heterozygosity, carrying the 17-bp duplication mutation in exon 14 and a 17-bp deletion in intron 15 that disrupts proper mRNA splicing.
To confirm that these mutations were pathogenic, we analyzed Epstein-Barr virus (EBV)-transformed lymphocytes derived from affected individuals from families 3 (E326K substitution) and 7 (17-bp duplication and intron 15 deletion). The samples from the severely affected individual (family 3) and mildly affected individuals (family 7) had much lower concentrations of PNKP protein than did those from unaffected or heterozygous family members (Fig. 3b) . RT-PCR analysis showed that the intron 15 deletion in family 7 disrupts mRNA splicing and causes skipping of exon 15; a barely detectable level of properly spliced mRNA remains (Fig. 3c) . The low concentrations of PNKP protein and the indistinguishable phenotype among severely affected individuals from families 1-6 suggest that all of these mutations impair PNKP severely or completely; in contrast, the individuals from family 7, who have a slightly milder phenotype and carry one noncoding mutation, may retain some PNKP activity.
Unexpectedly, despite their diverse ancestries (Saudi, Turkish and mixed European), all chromosomes with the 17-bp duplication mutation seem to share the same haplotype for 18 SNPs in or near the PNKP locus (Supplementary Fig. 4a) . The low frequency of this mutated haplotype (Supplementary Fig. 4b ) suggests that the 17-bp l e t t e r s duplication in exon 14 is probably of shared origin and very old in all or most of these families. Nonetheless, the mutation shows an extremely low carrier frequency in the general population, as the 17-bp duplication mutation was absent in 1,080 Middle Eastern or European-descended control chromosomes, and all other mutations were absent in all 280 control chromosomes screened. The PNKP protein has been implicated in repair of both doublestrand breaks (DSBs) and single-strand breaks (SSBs) 4, 5 , because its phosphatase domain removes 3′-phosphates and its kinase domain phosphorylates 5′-hydroxyl groups, steps that are required for DNA ligation 6 . PNKP's forkhead domain mediates interaction with the nonhomologous end-joining (NHEJ) complex via XRCC4 or with the SSB and base-excision repair (BER) pathways via XRCC1 ( Supplementary  Fig. 5 ) [4] [5] [6] [7] [8] . PNKP has been further implicated in the repair pathway disrupted in an ataxic neurodegenerative disease, spinocerebellar ataxia with axonal neuropathy (denoted SCAN1 and involving a l e t t e r s mutation in TDP1) (see Supplementary Fig. 5 for additional details). The abnormalities in a clinical irradiation-sensitivity test already reflect deficiencies in NHEJ, which is required to repair radiation-induced DSBs. Because PNKP potentially has roles in additional repair pathways, we tested cells in response to other DNA-damaging agents.
We examined the response of cells from individuals with MCSZ to free radical damage from hydrogen peroxide, which predominately requires BER, and camptothecin, which requires TDP1 via its activity on topoisomerase I, using an alkaline comet assay that detects both SSBs and DSBs by quantifying the amount of DNA that moves from a nucleus after electrophoresis. Typical nuclei with various degrees of DNA damage are shown in Figure 4a . We determined the relative amount of DNA damage by measuring the 'Percent tail DNA' (DNA that has moved out of the nucleus). The relative amount of DNA damage repair was quantified as the percent tail DNA after toxin exposure at various times of recovery (see Supplementary Table 2 for all data) and normalized to the maximum and minimum damage for each cell line in each experiment. MCSZ-derived cell lines were significantly impaired in their ability to repair hydrogen peroxide-induced damage (Fig. 4b) and were also delayed in repairing camptothecininduced damage (Fig. 4c) . MCSZ-derived cells were eventually able to repair the camptothecin-induced damage after 45 min, but they could not repair all hydrogen peroxide-induced damage even after 90 min. These data suggest that camptothecin-induced damage may be easier to repair than free radical damage in the setting of PNKP mutations. Although individuals with MCSZ do not develop the ataxia that characteristically results from TDP1 mutations that also cause camptothecin sensitivity 9, 10 , it may be that those we studied are too young (oldest 21 years) to show this characteristic, or there may be some mechanism compensating for the loss of PNKP.
Microcephaly can result from failure to produce enough neurons during development (primary microcephaly) or from degeneration after normal development. Individuals with MCSZ have no evidence of brain atrophy or clinical regression, making degeneration unlikely (see the Supplementary Note, Clinical Information, for further details). In situ hybridization indicated that human and mouse PNKP mRNAs are expressed in both dividing neuronal precursors in the cerebral cortical ventricular zone (VZ, Fig. 5a-c) and in postmitotic neurons of the cortical plate (CP, Fig. 5d) , which is consistent with potential roles in both dividing and postmitotic neurons. In addition, we found that when we used RNAi to reduce levels of Pnkp in dissociated mouse neurons in vitro, there was a small but statistically significant increase in apoptosis in both neuronal precursors and differentiated neurons (Supplementary Figs. 6 and 7 and Supplementary Table 3) compared to cells transfected with control plasmids. This indicates that microcephaly could result from apoptosis of precursors, differentiated neurons or both cell types.
Disruption of genes encoding NHEJ repair proteins can lead to microcephaly in humans and/or mice, as occurs in LIG4 syndrome, which involves mutations in Lig4 (refs. 11-13), in severe combined immunodeficiency with microcephaly, or as a result of mutations in NHEJ1 (encoding Cernunnos) 14 , Xrcc4 (ref. 15) , Xrcc6 (encoding Ku70) and Xrcc5 (encoding Ku80) 16 and Prkdc (encoding DNA-PKcs) 17 . However, disruption of NHEJ function is not known to cause seizures, which are a prominent clinical feature of MCSZ. In contrast, disruption of the BER and SSB pathways by deletion of Xrcc1 in mice produced normal brain size, but the mutant mice developed ataxia, loss of interneurons within the cerebellum and seizure-like behavior 18 . The intriguing similarity of phenotypes between humans with MCSZ who carry mutations in PNKP and mice with targeted deletion of Xrcc1 does suggest a potential common mechanism, demonstrating the requirement for the BER and SSB pathways in the prevention of seizures, potentially via an interneuron-specific requirement of the BER and SSB pathway. Therefore, the unique pattern of neurological symptoms of MCSZ may reflect a requirement for PNKP activity in multiple DNA repair pathways.
MeThoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. oNLINe MeThoDS Genetic screening. Family 1 underwent a genome-wide linkage screen using about 400 microsatellite markers in the ABI linkage mapping set MD v2.5 at an average density of 10 cM (Applied Biosystems) at the Children's Hospital in Boston (Genotyping Core facility). We performed genome-wide screens for families 3 and 4 at the Center for Inherited Disease Research using microsatellite markers that were also at an average spacing of 10 cM. We carried out fine mapping using polymorphic microsatellite markers from the ABI linkage mapping set HD v2.5 at an average density of 5 cM (Applied Biosystems) along with additional microsatellite markers identified using the UCSC Human Genome Browser 19 and synthesized primers (Sigma-Genosys). Two point and multipoint lod scores calculated using Allegro 20 assumed recessive inheritance, full penetrance and a disease allele frequency of 0.0001. All nucleotide numbers are in reference to cDNA, in which A (of the ATG start site) is +1, except for the intronic deletion, which is in reference to the genomic sequence, in which A of ATG of the translational start site is +1 (all from UCSC genome browser, NCBI Build 36.1).
PNKP protein blotting. For PNKP, we grew EBV-transformed lymphocytes in DMEM with 15% (vol/vol) FCS plus normocin. We lysed 2 × 10 5 cells in SDS loading buffer at 90 °C and fractionated them by SDS-PAGE. We transferred the proteins to Hybond-C Extra Nitrocellulose (GE Healthcare), stained them with Ponceau S solution (Sigma) and washed them in TBST (25 mM Tris base, 150 mM NaCl, 2.7 mM KCl, 0.1% Tween-20) before carrying out immunoblotting with anti-PNK (SK3195) 21 at a dilution of 1:1,000 in 5% (wt/vol) nonfat dried milk. We then washed the blots and probed them with goat anti-rabbit IgG-horseradish peroxidase (HRP) secondary antibody (DakoCytomation), which we detected with ECL detection reagents (GE Healthcare). The blot was then washed in TBST and re-probed with monoclonal anti-β-actin (Sigma) using rabbit anti-mouse IgG HRP (DakoCytomation) as a secondary antibody.
PNKP reverse transcriptase polymerase chain reaction. We grew EBVtransformed lymphocytes as described above. We isolated the RNA using the RNeasy Mini Kit (Qiagen). We used 5 µg of total RNA for first-strand synthesis with oligo(dT) primers using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen). We then used 1 µl of the product of the reverse transcriptase reaction was used in PCR with primers from Exon 10 to Exon 17.
Comet assays. We carried out alkaline comet assays using the protocol from CometAssay ES unit (Trevigen). Briefly, we grew affected individual-derived EBV-transformed lymphocytes as described above. Cells were obtained before treatment or exposed to 100 µM hydrogen peroxide (Sigma) or 10 µM camptothecin (Sigma) for 30 and 60 min, respectively, at 37 °C. After exposure, we immediately collected the cells for the 0 min recovery time point or washed them once, resuspended them in growth medium and incubated at 37 °C. Cells were subsequently at the times indicated. We then embedded the cells in low-melt agarose, plated them on microscope slides, lysed them, treated them with alkaline solution and then electrophoresed the slides in alkaline solution at 1 V cm −1 (21 V) with ~300 mA for 30 min. We washed and dried the slides were washed and stained the DNA with SYBR green. Images of nuclei and tails were taken with a Nikon TE2000-E fluorescent microscope with CCD camera, and we determined the percent tail DNA with CometScore 1.5 software (TriTek).
In situ hybridization. We performed human in situ hybridizations at the Human Developmental Biology Resource (Institute of Human Genetics, International Centre for Life, UK) with probes to antisense human PNKP cDNA (nucleotides +488-1500). We carried out mouse in situ hybridizations as described 22 , with an antisense probe derived from mouse Pnkp cDNA (+386-1566).
We calculated statistics using Microsoft Excel unless otherwise described. The 'Percent DNA repair' values in Figure 4 were determined by measuring the mean of the percent tail DNA in three separate wells (raw data are presented in Supplementary Fig. 5 ), using the combined percent tail DNA at 0 min recovery (maximum damage) and the minimum damage measured as full recovery for each individual cell line. We determined P values by comparing the baseline adjusted DNA repair level from three separate wells using a t-test that "compared" each MCSZ-deficient line to two normal control cell lines with a two-tailed distribution and homoscedastic test. PNKP mutation analysis. We performed PNKP protein alignments using MegAlign (Lasergene). We examined the three-dimensional structure of mouse Pnkp in MacPyMOL from previously published information 23 . The Branch Point analysis was done with Human Splicing Finder version 2.3 (http://www. umd.be/HSF/) Determination of the 17-bp duplication haplotype in exon 14. We determined Sequenom SNP genotypes in samples from affected and control individuals at the Molecular Genetics Core Facility at Children's Hospital Boston. We determined haplotypes were determined with Mendelian inheritance patterns for parents and offspring and with Phase haplotype-determining software [24] [25] [26] for control samples.
PNKP RNA interference studies. pSilencer 1.0 GFP had RNAi oligos targeted to mouse Pnkp mRNA identified via the Broad Institute RNAi Consortium shRNA Library, ligated into EcoRI and ApaI sites (Mo-Pnkp RNAi primers, Supplementary Table 3 ; Invitrogen). We dissected the cerebral cortices from embryonic day 13.5 Swiss-Webster mice and dissociated them using the Papain Dissociation System (Worthington Biochemical). We washed the cells twice in HBSS buffer (HyClone, Thermo Scientific) and transfected them using the Amaxa Nucleofactor 96 well shuttle system (Amaxa Biosystems) with either pSilencer mouse Pnkp-RNAi GFP or pSilencer GFP with or without pSport-human PNKP (Open Biosystems, Entrez clone ID BC057659). We grew the cells on poly-l-ornithine-treated (SigmaAldrich) Lab-Tek chamber slides with Permox (Nalge Nunc International) in DMEM with 10% (vol/vol) FBS for the Pax6 studies. For the NeuN studies, we changed the medium of the cultures to Neurobasal complete medium after 4 h. We fixed the cultures with 4% (vol/vol) paraformaldehyde 24 h after transfection. We carried out immunostaining in PBS with 0.2% (wt/vol) Triton X-100 and 10% (vol/vol) goat serum with chick anti-GFP (Abcam), rabbit anti-cleaved caspase 3 (Asp175) (Cell Signaling Technology), mouse anti-Pax6 (The Developmental Studies Hybridoma Bank) or mouse anti-NeuN (Chemicon). We detected the primary antibodies with anti-chicken IgG Alexa 488 (Invitrogen) and donkey anti-mouse IgG Cy3 or donkey anti-rabbit IgG Cy5 (Jackson ImmunoResearch). Images were obtained by looking for GFPpositive cells with a Nikon TE2000-E fluorescent microscope and Metamorph imaging software. We counted the cells from digital images with the counter blinded as to whether the cultures were derived from Pnkp-RNAi or control transfections. We calculated the P values in Supplementary Figure 7 using a G-test of goodness of fit with 5 degrees of freedom, a two-tailed P value and no Williams correction 27 .
Mouse Pnkp RNA interference testing. We tested the mouse (Mo) Pnkp RNAi construct Mo-Pnkp-DsRed or the human construct Hu-PNKPDsRed, both expressed by the pCAG-DsRed vector 28 . We transfected the RNAi control vector (empty vector)/Mo-Pnkp-DsRed fusion protein, Mo-Pnkp-RNAi/Mo-Pnkp-DsRed, RNAi-control/Hu-PNKP-DsRed fusion and Mo-Pnkp-RNAi/Hu-PNKP-DsRed into NIH-3T3 cells with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. We counted the cells after 24 h in culture. Random fields were chosen by the level of GFP expression, and the number of cells with high GFP expression was counted, followed by the number of cells expressing the Ds-Red fusion protein.
DsRed expression was nuclear, as expected from PNKP localization (data not shown). For protein blot analysis, we transfected NIH-3T3 cells as described above. After 24 h of culture, we lysed the cells using the protocol described above for PNKP protein blotting. After quantifying the protein using the BCA assay, we separated 25 µg of protein per lane by PAGE. We transferred the protein to a membrane, blocked it with Odyssey blocking buffer (Li-Cor Biosciences) and probed with mouse anti-actin (AC-15), rabbit anti-GFP (Molecular Probes) and rabbit anti-DsRed (Clontech). Primary antibody was detected with anti-mouse labeled with IRDye 700 or anti-rabbit IRDye 800 (Li-Cor Biosciences) and detected with Li-Cor imaging system. In the bar graph, protein amounts are normalized to RNAi control conditions.
